Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 1.71
(-0.29%)
SEK 1.71
(-0.29%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -446.98 Thousand SEK | -127.13% |
| 2022 | 1.64 Million SEK | 1.61% |
| 2021 | 1.62 Million SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -2990.00 SEK | -41.77% |
| 2017 | -2109.00 SEK | 84.12% |
| 2016 | -13.28 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | -988.81 Thousand SEK | 100.0% |
| 2024 Q1 | -697.01 Thousand SEK | -55.94% |
| 2023 FY | -446.98 Thousand SEK | -127.13% |
| 2023 Q1 | -1.55 Million SEK | -194.26% |
| 2023 Q4 | -446.98 Thousand SEK | 80.18% |
| 2023 Q3 | -2.25 Million SEK | -153.28% |
| 2023 Q2 | -890.42 Thousand SEK | 42.66% |
| 2022 Q2 | -1.65 Million SEK | 3.55% |
| 2022 Q3 | -2.44 Million SEK | -47.9% |
| 2022 Q4 | 1.64 Million SEK | 167.5% |
| 2022 FY | 1.64 Million SEK | 1.61% |
| 2022 Q1 | -1.71 Million SEK | -205.53% |
| 2021 Q1 | -621.79 Thousand SEK | 0.0% |
| 2021 FY | 1.62 Million SEK | 0.0% |
| 2021 Q4 | 1.62 Million SEK | 175.71% |
| 2021 Q3 | -2.14 Million SEK | -471.66% |
| 2021 Q2 | -374.6 Thousand SEK | 39.75% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2018 FY | -2990.00 SEK | -41.77% |
| 2017 FY | -2109.00 SEK | 84.12% |
| 2016 FY | -13.28 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | 22349400.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 89.33% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 93.736% |
| Mendus AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 102.999% |
| Intervacc AB (publ) | 10.48 Million SEK | 104.264% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -17779.44% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 101.269% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 104.929% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -22822.359% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 114.19% |
| Saniona AB (publ) | 1.00 SEK | 44698700.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 72.51% |
| Biovica International AB (publ) | 2.19 Million SEK | 120.327% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 44698700.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 121.49% |
| Xintela AB (publ) | 398 Thousand SEK | 212.308% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 163.855% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 48.206% |
| Amniotics AB (publ) | 534 Thousand SEK | 183.705% |
| 2cureX AB (publ) | -1000.00 SEK | -44598.6% |
| CombiGene AB (publ) | -1.79 Million SEK | 75.154% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 102.188% |
| Camurus AB (publ) | 100.95 Million SEK | 100.443% |
| Corline Biomedical AB | -3.85 Million SEK | 88.411% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 44798.6% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 110.444% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 104.565% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 90.932% |
| Cantargia AB (publ) | - SEK | Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 181.98% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 101.021% |
| Nanologica AB (publ) | 2.97 Million SEK | 115.035% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -39.185% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 103.774% |
| Alzinova AB (publ) | -3.27 Million SEK | 86.364% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 118.432% |
| Pila Pharma AB (publ) | 1.00 SEK | 44698700.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -29979.812% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 111.08% |
| Simris Alg AB (publ) | 1.09 Million SEK | 140.97% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 101.859% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 100.418% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 143.481% |